Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Claudia BanescuCenter for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Targu Mures, Romania.ORCID 0000-0002-3235-524X
Florin TriponCenter for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Targu Mures, Romania.ORCID 0000-0002-4297-9988
Anca S BojanDepartment of Hematology, The Oncology Institute "Ion Chiricuta" Cluj-Napoca, "Iuliu Hatieganu" University of Medicine and Pharmacy, 8, Victor Babes, Street, 400012 Cluj-Napoca, Romania.
Adrian P TrifaDepartment of Medical Genetics, "Iuliu Hatieganu" University of Medicine and Pharmacy, 8, Victor Babes, Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-0229-8643
Carmen MunteanDepartment of Clinical Science, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania.ORCID 0000-0002-8056-1339
George Andrei CrauciucCenter for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Targu Mures, Romania.
Alina BoglisCenter for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Targu Mures, Romania.ORCID 0000-0001-9025-0959
Marcela CandeaDepartment of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania.
Erzsebet LazarDepartment of Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania.
Laura JimbuDepartment of Hematology, The Oncology Institute "Ion Chiricuta" Cluj-Napoca, "Iuliu Hatieganu" University of Medicine and Pharmacy, 8, Victor Babes, Street, 400012 Cluj-Napoca, Romania.
Mihaela IancuDepartment of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy, 8, Victor Babes, Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-4557-5364
Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROIuliu Hațieganu University of Medicine and Pharmacy · RO
Funding
Unitatea Executiva Pentru Finantarea Invatamantului Superior Si A Cercetarii Stiintifice Universitare PN-III-P4-ID-PCE-2020-1928, within the PNCDI III, contract no. PCE 72/2021.
6 · The paper itself
Abstract
Toll-like receptors (TLRs) have an important role in innate immunity, and single nucleotide polymorphisms (SNPs) of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of TLR4 Rs4986791 Polymorphism and TLR9 Haplotypes with Acute Myeloid Leukemia Susceptibility: A Case-Control Study of Adult Patients. · full record | OpenQuestion